Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AML

Leukemia

CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK

Br J Haematol

Mehta P, Campbell V, Maddox J, Floisand Y, Kalakonda AJM, O'Nions J, Coats T, Nagumantry S, Hodgson K, Whitmill R, Amott I, Flynn G, Taussig D, Zhao R, Cunningham N, Roset M, Cuadras D, Medalla G, Kuter H, Park S, Legg A, Khan AB

doi: 10.1111/bjh.19622

Leukemia

Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients With AML Treated With Venetoclax and Azacitidine

Blood

Döhner H, Pratz KW, DiNardo CD, Wei AH, Jonas BA, Pullarkat V, Thirman MJ, Récher C, Schuh AC, Babu S, Li X, Ku G, Liu Z, Sun Y, Potluri J, Dail M, Chyla B, Pollyea DA

doi: 10.1182/blood.2024024944

Leukemia

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML

Blood

Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh MM, Mishra A, Muffly L, Kim HJ, Stelljes M, Najima Y, Onozawa M, Thomson KJ, Nagler A, Wei AH, Marcucci G, Chen C, Hasabou N, Rosales M, Hill JE, Gill SC, Nuthethi R, King D, Mendizabal AM, Devine SM, Horowitz MM, Chen YB

doi: 10.1182/blood.2024025154

ASH 2024

Leukemia

Quizartinib shows improved rates of composite complete remission and reduced need for re-induction in real-world patients with FLT3-ITD-mutated AML

Leukemia

Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment

Am J Hematol

Garciaz S, Dumas PY, Bertoli S, Sallman DA, Decroocq J, Belhabri A, Orvain C, Aspas Requena G, Simand C, Laribi K, Carré M, Santagostino A, Himberlin C, Peterlin P, Bonnet S, Chan O, Lancet J, Komrokji R, Vergez F, Chapuis N, Raskovalova T, Plesa A, Lhoumeau AC, Mineur A, Hospital MA, Pigneux A, Vey N, Récher C

doi: 10.1002/ajh.27417

ASH 2024

Leukemia

Real-world evidence confirms gilteritinib as an effective treatment option for R/R FLT3-mutated AML

Leukemia

Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT

Am J Hematol

Esteve J, Nagler A, Labopin M, Versluis J, Sanz J, Gedde-Dahl T, Burns D, Roeven M, Labussière-Wallet H, Borne PVD, Van Gorkom G, Contentin N, Neubauer A, Wagner-Drouet EM, Kröger N, Mohty M, Ciceri F

doi: 10.1002/ajh.27647

Leukemia

Venetoclax and Decitabine vs Intensive Chemotherapy as Induction for Young Patients with Newly Diagnosed AML

Blood

Lu J, Xue S, Wang Y, He X, Hu X, Miao M, Zhang Y, Tang Z, Xie J, Yang X, Xu M, Shen Y, Du F, Wu Q, Xue M, Wang Y, Deng A, Dou X, Xu Y, Dai H, Wu D, Chen S

doi: 10.1182/blood.2024027217

Leukemia

Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial

J Clin Oncol

Russell NH, Thomas A, Hills RK, Thomas I, Gilkes A, Almuina NM, Burns S, Marsh L, Vyas P, Metzner M, McCarthy N, Andrew G, Byrne J, Sellar RS, Kelly R, Cahalin P, Overgaard UM, Mehta P, Dennis M, Knapper S, Freeman SD

doi: 10.1200/JCO.24.00259

Related content

CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK

Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients With AML Treated With Venetoclax and Azacitidine

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML

Quizartinib shows improved rates of composite complete remission and reduced need for re-induction in real-world patients with FLT3-ITD-mutated AML

Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment

Real-world evidence confirms gilteritinib as an effective treatment option for R/R FLT3-mutated AML

Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT

Venetoclax and Decitabine vs Intensive Chemotherapy as Induction for Young Patients with Newly Diagnosed AML

Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial